For example, ALT positivity correlates with a worse prognosis for the HER2+ breast cancers, PanNETs, angiosarcoma, and all the soft tissue sarcomas, but with a better prognosis for osteosarcoma, astrocytoma, and neuroblastoma. This evidence concerns the gene ERBB2 and soft tissue sarcoma.